Imatinib mesylate in the treatment of hematologic malignancies

Expert Opinion on Biological Therapy

Volumn 7, Issue 10, 2007, Pages 1597-1611

  Piccaluga, Pier Paolo ^a,b   Rondoni, Michela ^a   Paolini, Stefania ^a   Rosti, Gianantonio ^a   Martinelli, Giovanni ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Imatinib mesylate; Molecular targeted therapy; Ph chromosome; Signal transduction; Tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; CYCLOSPORIN A; DEXAMETHASONE; DIHYDROPYRIDINE DERIVATIVE; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; ANTINEOPLASTIC AGENT; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1 PDGFRA FUSION PROTEIN, HUMAN; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LYMPHATIC LEUKEMIA; NEUTROPENIA; REVIEW; ANIMAL; BLOOD DISEASE; DRUG EFFECT; DRUG INTERACTION; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; METABOLISM; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; SIGNAL TRANSDUCTION; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE; FUSION PROTEINS, BCR-ABL; HEMATOLOGIC NEOPLASMS; HUMANS; HYPEREOSINOPHILIC SYNDROME; LEUKEMIA, LYMPHOCYTIC; LEUKEMIA, MYELOID, CHRONIC; MASTOCYTOSIS, SYSTEMIC; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MYELOPROLIFERATIVE DISORDERS; ONCOGENE PROTEINS, FUSION; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 35348815504     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.10.1597     Document Type: Review

References (92)

1. MANLEY PW, COWAN-JACOB SW, BUCHDUNGER E et al.: Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer (2002) 38(Suppl. 5):S19-S27.
2. LYSENG-WILLIAMSON K, JARVIS B: Imatinib. Drugs (2001) 61(12):1765-1774; discussion 1775-1766.
3. PICCALUGA PP, AGOSTINELLI C, CALIFANO A et al.: Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. (2007) 117(3):823-834.
4. CROOM KF, PERRY CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs (2003) 63(5):513-522; discussion 523-514.
5. BAIKIE AG, COURT-BROWN WM, BUCKTON KE et al.: A possible specific chromosome abnormality in human chronic myeloid leukaemia. Nature (1960) 188:1165-1166.
6. RADICH JP: Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol. Oncol. Clin. North Am. (2001) 15(1):21-36.
7. HOELZER D GN: Treatment of elderly patients with acute lymphoblastic leukemia. ASCO Education Book, 41st Annual Meeting, (13 - 17 May 2005):533-539.
8. REN R: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. (2005) 5(3):172-183.
9. HEISTERKAMP N, JENSTER G, TEN HOEVE J et al.: Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 344(6263):251-253.
10. DALEY GQ, VAN ETTEN RA, BALTIMORE D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247(4944):824-830.
11. PEAR WS, MILLER JP, XU L et al.: Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 92(10):3780- 3792.
12. KURZROCK R, GUTTERMAN JU, TALPAZ M: The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (1988) 319(15):990-998.
13. RASKIND WH, FERRARIS AM, NAJFELD V et al.: Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia (1993) 7(8):1163-1167.
14. BIERNAUX C, LOOS M, SELS A, HUEZ G, STRYCKMANS P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 86(8):3118-3122.
15. BOSE S, DEININGER M, GORA-TYBOR J, GOLDMAN JM, MELO JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood (1998) 92(9):3362-3367.
16. STEELMAN LS, POHNERT SC, SHELTON JG et al.: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia (2004) 18(2):189-218.
17. VAN ETTEN RA: Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leukemia Res. (2004) 28(Suppl. 1):S21-S28.
18. KANTARJIAN HM, GILES F, QUINTAS-CARDAMA A, CORTES J: Important therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res. (2007) 13(4):1089-1097.
19. BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56(1):100-104.
20. OKUDA K, WEISBERG E, GILLILAND DG, GRIFFIN JD: ARG tyrosine kinase activity is inhibited by STI571. Blood (2001) 97(8):2440-2448.
21. BUCHDUNGER E, CIOFFI CL, LAW N et al.: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. (2000) 295(1):139-145.
22. DEWAR AL, ZANNETTINO AC, HUGHES TP, LYONS AB: Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell cycle (2005) 4(7):851-853.
23. HEINRICH MC, GRIFFITH DJ, DRUKER BJ et al.: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 96(3):925-932.
24. VANDENBERGHE P, WLODARSKA I, MICHAUX L et al.: Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia (2004) 18(4):734-742.
25. COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348(13):1201-1214.
26. LA STARZA R, SPECCHIA G, CUNEO A et al.: The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/ PDGFRA but not genomic rearrangements of other tyrosine kinases. Haematologica (2005) 90(5):596-601.
27. PARDANANI A, BROCKMAN SR, PATERNOSTER SF et al.: FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood (2004) 104(10):3038- 3045.
28. ROCHE-LESTIENNE C, LEPERS S, SOENEN-CORNU V et al.: Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia (2005) 19(5):792-798.
29. PARDANANI A, KETTERLING RP, BROCKMAN SR et al.: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood (2003) 102(9):3093-3096.
30. STOVER EH, CHEN J, FOLENS C et al.: Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent. Proc. Natl. Acad. Sci. USA (2006) 103(21):8078-8083.
31. BUITENHUIS M, VERHAGEN LP, COOLS J, COFFER PJ: Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res. (2007) 67(8):3759-3766.
32. MARTINELLI G, RONDONI M, OTTAVIANI E, PAOLINI S, BACCARANI M: Hypereosinophilic syndrome and molecularly targeted therapy. Semin. Hematol. (2007) 44(2 Suppl. 2):S4-S16.
33. DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344(14):1038-1042.
34. TALPAZ M, SILVER RT, DRUKER BJ et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99(6):1928-1937.
35. SAWYERS CL, HOCHHAUS A, FELDMAN E et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood (2002) 99(10):3530-3539.
36. O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348(11):994-1004.
37. DRUKER BJ, GUILHOT F, O'BRIEN SG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. (2006) 355(23):2408-2417.
38. OTTMANN OG, DRUKER BJ, SAWYERS CL et al.: A Phase II study of imatinib in patients with relapsed or refractory Philaddphia chromosome-positive acute lymphoid leukemias. Blood (2002) 100(6):1965-1971.
39. WASSMANN B, PFEIFER H, SCHEURING U et al.: Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia (2002) 16(12):2358-2365.
40. SCHEURING UJ, PFEIFER H, WASSMANN B et al.: Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl- positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). Blood (2003) 101(1):85-90.
41. PICCALUGA PP, MALAGOLA M, AMABILE M et al.: The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica (2004) 89(10):1269-1271.
42. PFEIFER H, WASSMANN B, HOFMANN WK et al.: Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin. Cancer Res. (2003) 9(13):4674-4681.
43. WASSMANN B, PFEIFER H, GOEKBUGET N et al.: Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood (2006) 108(5):1469-1477.
44. THOMAS DA, FADERL S, CORTES J et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2004) 103(12):4396-4407.
45. TOWATARI M, YANADA M, USUI N et al.: Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood (2004) 104(12):3507-3512.
46. RIBERA J-M, ORIOL A, GONZALEZ M et al.: Treatment of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) with concurrent chemotherapy and imatinib mesylate. Blood (2004) 104:(Abstract 4483).
47. DHEDIN N, DOMBRET H, THOMAS X et al.: Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials. Leukemia (2006) 20(2):336-344.
48. HOELZER D, GOKBUGET N: Recent approaches in acute lymphoblastic leukemia in adults. Crit. Rev. Oncol. Hematol. (2000) 36(1):49-58.
49. VIGNETTI M, FAZI P, CIMINO G et al.: Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood (2007) 109(9):3676-3678.
50. OTTMANN OG, WASSMANN B, PFEIFER H et al.: Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer (2007) 109(10):2068-2076.
51. DELANNOY AL, LHERITIER V, THOMAS X et al.: Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph+ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy. An interim analysis of the GRAALL AFR09 Trial. Blood (2004) 104:(Abstract 2742).
52. RADICH J, GEHLY G, LEE A et al.: Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood (1997) 89(7):2602-2609.
53. WASSMANN B, PFEIFER H, STADLER M et al.: Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood (2005) 106(2):458- 463.
54. PICCALUGA PP, MARTINELLI G, RONDONI M, VISANI G, BACCARANI M: Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Exp. Opin. Biol. Ther. (2006) 6(10):1011-1022.
55. PICCALUGA PP, PAOLINI S, MARTINELLI G: Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Cancer (2007) 110(6):1178-1186.
56. GOTLIB J: Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol. (2005) 114(1):7-25.
57. BACCARANI M, CILLONI D, RONDONI M et al.: The efficacy of imatinib mesylate in patients with FIP1l1-PDGFRα-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica (2007) (In Press).
58. FRICKHOFEN N, MARKER-HERMANN E, REITER A et al.: Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann. Hematol. (2004) 83(7):477-480.
59. ROSE C, DUPIRE S, ROCHE-LESTIENNE C et al.: Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia (2004) 18(2):354- 355.
60. CERVETTI G, GALIMBERTI S, CARULLI G, PETRINI M: Imatinib therapy in hypereosinophilic syndrome: a case of molecular remission. Leuk. Res. (2005) 29(9):1097-1098.
61. JOVANOVIC JV, SCORE J, WAGHORN K et al.: Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood (2007) 109(11):4635-4640.
62. METCALFE DD: Classification and diagnosis of mastocytosis: current status. J. Investig. Dermatol. (1991) 96(3):S2-S4.
63. METCALFE DD: The treatment of mastocytosis: an overview. J. Investig. Dermatol. (1991) 96(3):S55-S56; discussion S56-S59.
64. GALLI SJ: New concepts about the mast cell. N. Engl. J. Med. (1993) 328(4):257-265.
65. LONGLEY BJ Jr, MORGANROTH GS, TYRRELL L et al.: Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N. Engl. J. Med. (1993) 328(18):1302-1307.
66. LONGLEY BJ, TYRRELL L, LU SZ et al.: Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. (1996) 12(3):312-314.
67. HEINRICH MC, BLANKE CD, DRUKER BJ, CORLESS CL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. (2002) 20(6):1692-1703.
68. FURITSU T, TSUJIMURA T, TONO T et al.: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. (1993) 92(4):1736-1744.
69. HERZIG RH, BORTIN MM, BARRETT AJ et al.: Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet (1987) 1(8536):786-789.
70. PARDANANI A, ELLIOTT M, REEDER T et al.: Imatinib for systemic mast-cell disease. Lancet (2003) 362(9383):535-536.
71. DROOGENDIJK HJ, KLUIN-NELEMANS HJ, VAN DOORMAAL JJ et al.: Imatinib mesylate in the treatment of systemic mastocytosis: a Phase II trial. Cancer (2006) 107(2):345-351.
72. AKIN C, BROCKOW K, D'AMBROSIO C et al.: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp. Hematol. (2003) 31(8):686-692.
73. APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. (2002) 347(7):481-487.
74. DAVID M, CROSS NC, BURGSTALLER S et al.: Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood (2007) 109(1):61-64.
75. PICCALUGA PP, AGOSTINELLI C, ZINZANI PL et al.: Expression of platelet-derived growth factor receptor α in peripheral T-cell lymphoma not otherwise specified. Lancet Oncol. (2005) 6(6):440.
76. KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
77. ROSTI G, MARTINELLI G, BACCARANI M: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat. Med. (2007) 13(1):15; author reply 15-16.
78. ATALLAH E, KANTARJIAN H, CORTES J: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat. Med. (2007) 13(1):14; author reply 15-16.
79. ATALLAH E, DURAND JB, KANTARJIAN H, CORTES J: Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood (2007) 110(4):1233-1237.
80. HATFIELD A, OWEN S, PILOT PR: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat. Med. (2007) 13(1):13; author reply 15-16.
81. SCHINDLER T, BORNMANN W, PELLICENA P et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289(5486):1938-1942.
82. CORBIN AS, BUCHDUNGER E, PASCAL F, DRUKER BJ: Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J. Biol. Chem. (2002) 277(35):32214-32219.
83. CORBIN AS, LA ROSEE P, STOFFREGEN EP, DRUKER BJ, DEININGER MW: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) 101(11):4611-4614.
84. GAMBACORTI-PASSERINI CB, GUNBY RH, PIAZZA R et al.: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. (2003) 4(2):75-85.
85. SHAH NP, TRAN C, LEE FY et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305(5682):399- 401.
86. HOCHHAUS A, ERBEN P, ERNST T, MUELLER MC: Resistance to targeted therapy in chronic myelogenous leukemia. Semin. Hematol. (2007) 44(1 Suppl. 1):S15-S24.
87. BRANFORD S, RUDZKI Z, WALSH S et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 102(1):276-283.
88. SOVERINI S, MARTINELLI G, ROSTI G et al.: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J. Clin. Oncol. (2005) 23(18):4100-4109.
89. HOFMANN WK, KOMOR M, HOELZER D, OTTMANN OG: Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk. Lymphoma (2004) 45(4):655-660.
90. VON BUBNOFF N, PESCHEL C, DUYSTER J: Resistance of Philadelphia- chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia (2003) 17(5):829-838.
91. PFEIFER H, WASSMANN B, PAVLOVA A et al.: Pattern and evolution of BCR-ABL kinase domain mutations in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) developing resistance to imatinib. Blood (2005) 106(11):(Abstract 147).
92. LEE S, KIM DW, KIM YJ et al.: Minimal residual disease-based role of imatinib mesylate as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2003) 102(8):3068-3070.